Efficacy and Safety of Spesolimab and Deucravacitinib

EP: 1.Recent Approvals in the Management of Plaque Psoriasis

EP: 2.Clinical Experiences With Bimekizumab

EP: 3.Efficacy and Safety of Bimekizumab in Plaque Psoriasis

Now Viewing

EP: 4.Efficacy and Safety of Spesolimab and Deucravacitinib

EP: 5.Nonsteroidal Topical Treatments for Plaque Psoriasis

EP: 6.Pediatric Plaque Psoriasis Treatment and Considerations for Patients With Skin of Color

EP: 7.Looking Ahead for the Management of Plaque Psoriasis

EP: 8.Key Takeaways For the Management of Plaque Psoriasis

This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.

The panelists delve into the introduction and remarkable efficacy of spesolimab for generalized pustular psoriasis (GPP), emphasizing its life-saving potential. Dr. Khattri recounts a case where a patient experiencing a severe flare of GPP achieved rapid improvement within hours of receiving a single infusion of spesolimab.

They discuss the profound impact of spesolimab's fast-acting nature on patients' quality of life, particularly those with severe manifestations of GPP. Dr. Lebwohl highlights the before-and-after photographs demonstrating the dramatic transformation observed in patients treated with spesolimab.

The conversation shifts to deucravacitinib, another oral option for psoriasis treatment with a distinct mechanism of action. Dr. Khattri explains that deucravacitinib's selective inhibition of TYK2 receptor distinguishes it from other Janus kinase (JAK) inhibitors, resulting in a favorable safety profile without the typical side effects associated with JAK blockade.

Dr. Lebwohl underscores the efficacy of deucravacitinib in palmoplantar psoriasis, a challenging-to-treat subtype, citing promising data indicating improvement in palm and sole lesions. Additionally, they discuss the potential use of deucravacitinib in other neutrophilic diseases like pyoderma gangrenosum and Sweet’s syndrome.

Regarding side effects, Dr. Khattri addresses the common occurrence of oral candidiasis with IL-17 blockade but reassures patients of its manageable nature compared to its efficacy in treating psoriasis.

The panelists conclude that spesolimab and deucravacitinib represent significant advancements in psoriasis treatment, offering rapid and durable responses with favorable safety profiles, thereby improving the management of severe psoriasis and related conditions.

Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.